Rationally designed multitarget agents against inflammation and pain

Current Medicinal Chemistry

Volumn 20, Issue 13, 2013, Pages 1783-1799

  Hwang, S H ^a   Wecksler, A T ^a   Wagner, K ^a   Hammock, B D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclooxygenase (COX); Cytochrome P450 (CYP); Dual inhibitors; Lipoxygenase (LOX); Multitarget inhibitors; Soluble epoxide hydrolase (sEH)

Indexed keywords

1 (7 TERT BUTYL 2,3 DIHYDRO 3,3 DIMETHYLBENZO[B]FURAN 5 YL) 4 CYCLOPROPYL 1 BUTANONE; 2 MERCAPTOHEXANOIC ACID; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 6 HYDROXY 5,7 DIMETHYL 2 METHYLAMINO 4 (3 PYRIDYLMETHYL)BENZOTHIAZOLE; BENOXAPROFEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DARBUFELONE; DICLOFENAC; E 6700; IBUPROFEN; INDOMETACIN; L 652 343; LICOFELONE; N [5 (4 FLUOROPHENOXY) 2 THIENYL]METHANESULFONAMIDE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENIDONE; PIRINIXIC ACID; S 2474; SALAZOSULFAPYRIDINE; SORAFENIB; TEBUFELONE; TENIDAP; TEPOXALIN; UNCLASSIFIED DRUG; YS 121;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG SCREENING; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; INFLAMMATION; MOLECULAR INTERACTION; NONHUMAN; PAIN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; INFLAMMATION; LIPOXYGENASE; LIPOXYGENASE INHIBITORS; MOLECULAR TARGETED THERAPY; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SIGNAL TRANSDUCTION;

EID: 84877948851     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320130013     Document Type: Article

References (203)

1. Piomelli, D. Arachidonic acid in cell signaling. Curr. Opin. Cell. Biol., 1993, 5, 274-280.
2. Capdevila, J.H.; Falck, J.R.; Estabrook, R.W. Cytochrome P450 and the arachidonate cascade. FASEB J, 1992, 6, 731-736.
3. Vane, J.R.; Flower, R.J.; Botting, R.M. History of aspirin and its mechanism of action. Stroke, 1990, 21 (12 Suppl), IV12-23.
4. Melnikova, I. Pain market. Nat. Rev. Drug Discov., 2010, 9, 589-590.
5. Green, G.A. Understanding NSAIDs: From aspirin to COX-2. Clin. Cornerstone, 2001, 3, 50-60.
6. Griswold, D.E.; Adams, J.L. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date. Med. Res. Rev., 1996, 16, 181-206.
7. Wallace, J.L.; Ma, L. Inflammatory mediators in gastrointestinal defense and injury. Exp. Biol. Med., 2001, 226, 1003-1015.
8. Hla, T.; Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 1992, 89, 7384-7388.
9. Jones, D.A.; Carlton, D.P.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J.Biol. Chem., 1993, 268, 9049-9054.
10. Fletcher, B.S.; Lim, R.W.; Varnum, B.C.; Kujubu, D.A.; Koski, R.A.; Herschman, H.R. Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J. Biol. Chem., 1991, 266, 14511-14518.
11. FitzGerald, G.A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. New Engl. J. Med., 2001, 345, 433-442.
12. Scheiman, J.M. Gastroduodenal safety of cyclooxygenase-2 inhibitors. Curr. Pharm. Des., 2003, 9, 2197-2206.
13. Mukherjee, D.; Nissen, S.E.; Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959.
14. Patscheke, H. Thromboxane A2/prostaglandin H2 receptor antagonists. A new therapeutic principle. Stroke, 1990, 21, IV139-142.
15. Moncada, S.; Vane, J.R. The role of prostacyclin in vascular tissue. Fed. Proc., 1979, 38, 66-71.
16. Bing, R.J.; Lomnicka, M. Why do cyclooxygenase-2 inhibitors cause cardiovascular events? J. Am. Coll. Cardiol., 2002, 39, 521-522.
17. Fitzgerald, G.A. Coxibs and cardiovascular disease. New Engl. J. Med., 2004, 351, 1709-1711.
18. Cheng, Y.; Austin, S.C.; Rocca, B.; Koller, B.H.; Coffman, T.M.; Grosser, T.; Lawson, J.A.; FitzGerald, G.A. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science, 2002, 296, 539-541.
19. Liu, J.Y.; Li, N.; Yang, J.; Qiu, H.; Ai, D.; Chiamvimonvat, N.; Zhu, Y.; Hammock, B.D. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc. Natl. Acad. Sci. USA, 2010, 107, 17017-17022.
20. Garcia Rodriguez, L.A.; Barreales Tolosa, L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology, 2007, 132, 498-506.
21. Hippisley-Cox, J.; Coupland, C.; Logan, R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ, 2005, 331, 1310-1316.
22. Calder, P.C. Long-chain fatty acids and inflammation. Proc. Nutr. Soc., 2012, 1-6.
23. Dennis, E.A.; Cao, J.; Hsu, Y.H.; Magrioti, V.; Kokotos, G. Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev., 2011, 111, 6130-6185.
24. Smith, W. Eicosanoid nomenclature. Prostaglandins, 1989, 38, 125-133.
25. Ricciotti, E.; FitzGerald, G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol., 2011, 31, 986-1000.
26. Samuelsson, B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science, 1983, 220, 568-575.
27. Spokas, E.G.; Rokach, J.; Wong, P.Y. Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Methods Mol. Biol., 1999, 120, 213-247.
28. McMahon, B.; Mitchell, S.; Brady, H.R.; Godson, C. Lipoxins: Revelations on resolution. Trends Pharmacol. Sci., 2001, 22, 391-395.
29. Miyata, N.; Roman, R.J. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J. Smooth Muscle Res., 2005, 41, 175-193.
30. Sarkis, A.; Lopez, B.; Roman, R.J. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr. Opin. Nephrol. Hypertens., 2004, 13, 205-214.
31. Newman, J.W.; Morisseau, C.; Hammock, B.D. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog. Lipid Res., 2005, 44, 1-51.
32. Smith, W.L.; Urade, Y.; Jakobsson, P.J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev., 2011, 111, 5821-5865.
33. Santovito, D.; Mezzetti, A.; Cipollone, F. Cyclooxygenase and prostaglandin synthases: Roles in plaque stability and instability in humans. Curr. Opin. Lipidol., 2009, 20, 402-408.
34. Rouzer, C.A.; Marnett, L.J. Cyclooxygenases: Structural and functional insights. J. Lipid Res., 2009, 50 Suppl, S29-34.
35. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Isakson, P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv. Exp. Med. Biol., 1997, 400A, 167-170.
36. Vane, J.R.; Bakhle, Y.S.; Botting, R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
37. Fu, J.Y.; Masferrer, J.L.; Seibert, K.; Raz, A.; Needleman, P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem., 1990, 265, 16737-16740.
38. Beiche, F.; Scheuerer, S.; Brune, K.; Geisslinger, G.; Goppelt-Struebe, M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett., 1996, 390, 165-169.
39. Maslinska, D.; Kaliszek, A.; Opertowska, J.; Toborowicz, J.; Deregowski, K.; Szukiewicz, D. Constitutive expression of cyclooxygenase-2 (COX-2) in developing brain. A. Choroid plexus in human fetuses. Folia Neuropathol., 1999, 37, 287-291.
40. Komhoff, M.; Wang, J.L.; Cheng, H.F.; Langenbach, R.; McKanna, J.A.; Harris, R.C.; Breyer, M.D. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int., 2000, 57, 414-422.
41. Ohki, S.; Ogino, N.; Yamamoto, S.; Hayaishi, O., Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem., 1979, 254, 829-836.
42. Smith, W.L.; Song, I. The enzymology of prostaglandin endoperoxide H synthases-1 and-2. Prostag. Oth. Lipid M., 2002, 68-69, 115-128.
43. Needleman, P.; Turk, J.; Jakschik, B.A.; Morrison, A.R.; Lefkowith, J.B. Arachidonic acid metabolism. Annu. Rev. Biochem., 1986, 55, 69-102.
44. Thoren, S.; Weinander, R.; Saha, S.; Jegerschold, C.; Pettersson, P.L.; Samuelsson, B.; Hebert, H.; Hamberg, M.; Morgenstern, R.; Jakobsson, P.J. Human microsomal prostaglandin E synthase-1: Purification, functional characterization, and projection structure determination. J. Biol. Chem., 2003, 278, 22199-22209.
45. Friesen, R.W.; Mancini, J.A. Microsomal prostaglandin E2 synthase-1 (mPGES-1): A novel anti-inflammatory therapeutic target. J. Med. Chem., 2008, 51, 4059-4067.
46. Murakami, M.; Nakashima, K.; Kamei, D.; Masuda, S.; Ishikawa, Y.; Ishii, T.; Ohmiya, Y.; Watanabe, K.; Kudo, I., Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and-2. J. Biol. Chem., 2003, 278, 37937-37947.
47. Murakami, M.; Naraba, H.; Tanioka, T.; Semmyo, N.; Nakatani, Y.; Kojima, F.; Ikeda, T.; Fueki, M.; Ueno, A.; Oh, S.; Kudo, I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem., 2000, 275, 32783-32792.
48. Wong, P.Y.; Lai, P.S.; Falck, J.R. Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes. Prostag. Oth. Lipid M., 2000, 62(4), 321-333.
49. von Euler, U.S. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J. Physiol.-London, 1936, 88, 213-234.
50. Woodward, D.F.; Jones, R.L.; Narumiya, S., International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev., 2011, 63, 471-538.
51. Wolfe, M.M.; Lichtenstein, D.R.; Singh, G., Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New Engl. J. Med., 1999, 340, 1888-1899.
52. Moncada, S.; Vane, J.R., Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev., 1978, 30, 293-331.
53. Orehek, J.; Douglas, J.S.; Lewis, A.J.; Bouhuys, A., Prostaglandin regulation of airway smooth muscle tone. Nat. New Biol., 1973, 245, 84-85.
54. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Prostanoid receptors: Structures, properties, and functions. Physiol. Rev., 1999, 79, 1193-1226.
55. Funk, C.D., Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science, 2001, 294, 1871-1875.
56. Zeilhofer, H.U. Prostanoids in nociception and pain. Biochem. Pharmacol., 2007, 73, 165-174.
57. Samad, T.A.; Sapirstein, A.; Woolf, C.J. Prostanoids and pain: Unraveling mechanisms and revealing therapeutic targets. Trends Mol. Med., 2002, 8, 390-396.
58. Khanapure, S.P.; Garvey, D.S.; Janero, D.R.; Letts, L.G. Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem., 2007, 7, 311-340.
59. Kuhn, H., Structural basis for the positional specificity of lipoxygenases. Prostag. Oth. Lipid M., 2000, 62, 255-270.
60. Serhan, C.N.; Hamberg, M.; Samuelsson, B. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA, 1984, 81, 5335-5339.
61. Hussain, H.; Shornick, L.P.; Shannon, V.R.; Wilson, J.D.; Funk, C.D.; Pentland, A.P.; Holtzman, M.J. Epidermis contains platelettype 12-lipoxygenase that is overexpressed in germinal layer keratinocytes in psoriasis. Am. J. physiol., 1994, 266, C243-253.
62. Harats, D.; Shaish, A.; George, J.; Mulkins, M.; Kurihara, H.; Levkovitz, H.; Sigal, E., Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2100-2105.
63. Rouzer, C.A.; Kargman, S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J. Biol. Chem., 1988, 263, 10980-10988.
64. Ford-Hutchinson, A.W. FLAP: A novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol. Sci., 1991, 12, 68-70.
65. Borgeat, P.; Hamberg, M.; Samuelsson, B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J. Biol. Chem., 1976, 251, 7816-7820.
66. Rouzer, C.A.; Matsumoto, T.; Samuelsson, B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc. Natl. Acad. Sci. USA, 1986, 83, 857-861.
67. Radmark, O.; Shimizu, T.; Jornvall, H.; Samuelsson, B. Leukotriene A4 hydrolase in human leukocytes. Purification and properties. J. Biol. Chem., 1984, 259, 12339-12345.
68. Lam, B.K.; Frank Austen, K. Leukotriene C4 synthase. A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes. Am. J. Respir. Crit. Care Med., 2000, 161, S16-19.
69. Haeggstrom, J.Z.; Funk, C.D. Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease. Chem. Rev., 2011, 111, 5866-5898.
70. Peters-Golden, M.; Henderson, W.R., Jr. Leukotrienes. New Engl. J. Med., 2007, 357, 1841-1854.
71. Tager, A.M.; Luster, A.D., BLT1 and BLT2: The leukotriene B(4) receptors. Prostag. Leukotr. Ess., 2003, 69, 123-134.
72. Heise, C.E.; O'Dowd, B.F.; Figueroa, D.J.; Sawyer, N.; Nguyen, T.; Im, D.S.; Stocco, R.; Bellefeuille, J.N.; Abramovitz, M.; Cheng, R.; Williams, D.L., Jr.; Zeng, Z.; Liu, Q.; Ma, L.; Clements, M.K.; Coulombe, N.; Liu, Y.; Austin, C.P.; George, S.R.; O'Neill, G.P.; Metters, K.M.; Lynch, K.R.; Evans, J.F. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem., 2000, 275, 30531-30536.
73. Lynch, K.R.; O'Neill, G.P.; Liu, Q.; Im, D.S.; Sawyer, N.; Metters, K.M.; Coulombe, N.; Abramovitz, M.; Figueroa, D.J.; Zeng, Z.; Connolly, B.M.; Bai, C.; Austin, C.P.; Chateauneuf, A.; Stocco, R.; Greig, G.M.; Kargman, S.; Hooks, S.B.; Hosfield, E.; Williams, D.L., Jr.; Ford-Hutchinson, A.W.; Caskey, C.T.; Evans, J.F. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature, 1999, 399, 789-793.
74. Ford-Hutchinson, A.W.; Bray, M.A.; Doig, M.V.; Shipley, M.E.; Smith, M.J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature, 1980, 286, 264-265.
75. Bjork, J.; Hedqvist, P.; Arfors, K.E., Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes. Inflammation, 1982, 6, 189-200.
76. Samuelsson, B.; Dahlen, S.E.; Lindgren, J.A.; Rouzer, C.A.; Serhan, C.N., Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science, 1987, 237, 1171-1176.
77. Hay, D.W.; Torphy, T.J.; Undem, B.J., Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. Trends Pharmacol. Sci., 1995, 16, 304-309.
78. Rioux, K.P.; Wallace, J.L. Mast cell activation augments gastric mucosal injury through a leukotriene-dependent mechanism. Am. J. Physiol., 1994, 266, G863-869.
79. Vaananen, P.M.; Keenan, C.M.; Grisham, M.B.; Wallace, J.L. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation, 1992, 16, 227-240.
80. Lewis, R.A.; Austen, K.F.; Soberman, R.J., Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. New Engl. J. Med., 1990, 323, 645-655.
81. Capdevila, J.; Chacos, N.; Werringloer, J.; Prough, R.A.; Estabrook, R.W., Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc. Natl. Acad. Sci. USA, 1981, 78, 5362-5366.
82. Capdevila, J.; Marnett, L.J.; Chacos, N.; Prough, R.A.; Estabrook, R.W. Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proc. Natl. Acad. Sci. USA, 1982, 79, 767-770.
83. Morrison, A.R.; Pascoe, N. Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex. Proc. Natl. Acad. Sci. USA, 1981, 78, 7375-7378.
84. Oliw, E.H.; Oates, J.A. Oxygenation of arachidonic acid by hepatic microsomes of the rabbit. Mechanism of biosynthesis of two vicinal dihydroxyeicosatrienoic acids. Biochim. Biophys. Acta, 1981, 666, 327-340.
85. Oliw, E.H.; Guengerich, F.P.; Oates, J.A. Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. J. Biol. Chem., 1982, 257, 3771-3781.
86. Elbekai, R.H.; El-Kadi, A.O. Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol. Therapeut., 2006, 112, 564-587.
87. Roman, R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev., 2002, 82, 131-185.
88. Carroll, M.A.; McGiff, J.C. A new class of lipid mediators: Cytochrome P450 arachidonate metabolites. Thorax, 2000, 55 Suppl 2, S13-16.
89. Zeldin, D.C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem., 2001, 276, 36059-36062.
90. Kaspera, R.; Totah, R.A. Epoxyeicosatrienoic acids: Formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin. Drug Metab. Toxicol., 2009, 5, 757-771.
91. Inceoglu, B.; Schmelzer, K.R.; Morisseau, C.; Jinks, S.L.; Hammock, B.D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostag. Oth. Lipid M., 2007, 82, 42-49.
92. Pozzi, A.; Macias-Perez, I.; Abair, T.; Wei, S.; Su, Y.; Zent, R.; Falck, J.R.; Capdevila, J.H. Characterization of 5,6-and 8,9-epoxyeicosatrienoic acids (5,6-and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem., 2005, 280, 27138-27146.
93. Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D.C.; Liao, J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 1999, 285, 1276-1279.
94. Fisslthaler, B.; Popp, R.; Kiss, L.; Potente, M.; Harder, D.R.; Fleming, I.; Busse, R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 1999, 401, 493-497.
95. Rosolowsky, M.; Campbell, W.B. Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim. Biophys. Acta, 1996, 1299, 267-277.
96. Fleming, I., DiscrEET regulators of homeostasis: Epoxyeico satrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends Pharmacol. Sci., 2007, 28, 448-452.
97. Zeldin, D.C.; Kobayashi, J.; Falck, J.R.; Winder, B.S.; Hammock, B.D.; Snapper, J.R.; Capdevila, J.H. Regio-and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J. Biol. Chem., 1993, 268, 6402-6407.
98. Yu, Z.; Xu, F.; Huse, L.M.; Morisseau, C.; Draper, A.J.; Newman, J.W.; Parker, C.; Graham, L.; Engler, M.M.; Hammock, B.D.; Zeldin, D.C.; Kroetz, D.L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res., 2000, 87, 992-998.
99. Imig, J.D., Epoxides and soluble epoxide hydrolase in cardio vascular physiology. Physiol. Rev., 2012, 92, 101-130.
100. Arnold, C.; Konkel, A.; Fischer, R.; Schunck, W.H. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol. Rep., 2010, 62, 536-547.
101. Morisseau, C.; Inceoglu, B.; Schmelzer, K.; Tsai, H.J.; Jinks, S.L.; Hegedus, C.M.; Hammock, B.D. Naturally occurring mono epoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J. Lipid Res., 2010, 51, 3481-3490.
102. Wagner, K.; Inceoglu, B.; Hammock, B.D. Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. Prostag. Oth. Lipid M., 2011, 96, 76-83.
103. Spector, A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res., 2009, 50 Suppl, S52-56.
104. Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T.S.; Fang, X.; Zhu, Y.; Spector, A.A.; Gill, S.; Morisseau, C.; Hammock, B.D.; Shyy, J.Y. The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA, 2005, 102, 16747-16752.
105. Falck, J.R.; Reddy, L.M.; Reddy, Y.K.; Bondlela, M.; Krishna, U.M.; Ji, Y.; Sun, J.; Liao, J.K. 11,12-epoxyeicosatrienoic acid (11,12-EET): Structural determinants for inhibition of TNF-alphainduced VCAM-1 expression. Bioorg. Med. Chem. Lett., 2003, 13, 4011-4014.
106. Node, K.; Ruan, X.L.; Dai, J.; Yang, S.X.; Graham, L.; Zeldin, D.C.; Liao, J.K. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeico satrienoic acids. J. Biol. Chem., 2001, 276, 15983-15989.
107. Schmelzer, K.R.; Kubala, L.; Newman, J.W.; Kim, I.H.; Eiserich, J.P.; Hammock, B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA, 2005, 102, 9772-9777.
108. Norwood, S.; Liao, J.; Hammock, B.D.; Yang, G.Y. Epoxyeico satrienoic acids and soluble epoxide hydrolase: Potential therapeutic targets for inflammation and its induced carcinogenesis. Am. J. Transl. Res., 2010, 2, 447-457.
109. Inceoglu, B.; Jinks, S.L.; Ulu, A.; Hegedus, C.M.; Georgi, K.; Schmelzer, K.R.; Wagner, K.; Jones, P.D.; Morisseau, C.; Hammock, B.D. Soluble epoxide hydrolase and epoxyeico satrienoic acids modulate two distinct analgesic pathways. Proc. Natl. Acad. Sci. USA, 2008, 105, 18901-18906.
110. Christie, M.J. Cellular neuroadaptations to chronic opioids: Tolerance, withdrawal and addiction. Br. J. Pharmacol., 2008, 154, 384-396.
111. Zeilhofer, H.U.; Brune, K. Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol. Sci., 2006, 27, 467-474.
112. Wagner, K.; Inceoglu, B.; Gill, S.S.; Hammock, B.D. Epoxy genated fatty acids and soluble epoxide hydrolase inhibition: Novel mediators of pain reduction. J. Agric. Food Chem., 2011, 59, 2816-2824.
113. Stables, M.J.; Gilroy, D.W. Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res., 2011, 50, 35-51.
114. Townsley, M.I.; King, J.A.; Alvarez, D.F. Ca2+ channels and pulmonary endothelial permeability: Insights from study of intact lung and chronic pulmonary hypertension. Microcirculation, 2006, 13, 725-739.
115. Loot, A.E.; Fleming, I. Cytochrome P450-derived epoxyeico satrienoic acids and pulmonary hypertension: Central role of transient receptor potential C6 channels. J. Cardiovasc. Pharmacol., 2011, 57, 140-147.
116. Mustafa, S.; Sharma, V.; McNeill, J.H. Insulin resistance and endothelial dysfunction: Are epoxyeicosatrienoic acids the link? Exp. Clin. Cardiol., 2009, 14, e41-50.
117. Luria, A.; Bettaieb, A.; Xi, Y.; Shieh, G.J.; Liu, H.C.; Inoue, H.; Tsai, H.J.; Imig, J.D.; Haj, F.G.; Hammock, B.D. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc. Natl. Acad. Sci. USA, 2011, 108, 9038-9043.
118. Hao, C.M.; Breyer, M.D. Roles of lipid mediators in kidney injury. Semin. Nephrol., 2007, 27, 338-351.
119. Imig, J.D. Targeting epoxides for organ damage in hypertension. J. Cardiovasc. Pharmacol., 2010, 56, 329-335.
120. Xu, X.; Zhang, X.A.; Wang, D.W. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv. Drug Deliv. Rev., 2011, 63, 597-609.
121. Sato, M.; Yokoyama, U.; Fujita, T.; Okumura, S.; Ishikawa, Y., The roles of cytochrome p450 in ischemic heart disease. Curr. Drug Metab., 2011, 12, 526-532.
122. Imig, J.D.; Hammock, B.D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov., 2009, 8, 794-805.
123. Panigrahy, D.; Kaipainen, A.; Greene, E.R.; Huang, S. Cytochrome P450-derived eicosanoids: The neglected pathway in cancer. Cancer Metastasis Rev., 2010, 29, 723-735.
124. Wagner, K.; Inceoglu, B.; Hammock, B.D. Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. Prostag. Oth. Lipid M., 2011, 96, 76-83.
125. Asako, H.; Kubes, P.; Wallace, J.; Gaginella, T.; Wolf, R.E.; Granger, D.N. Indomethacin-induced leukocyte adhesion in mesenteric venules: Role of lipoxygenase products. Am. J. Physiol., 1992, 262, G903-908.
126. Gilroy, D.W.; Tomlinson, A.; Willoughby, D.A. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. J. Pharmacol., 1998, 355, 211-217.
127. Knapp, H.R.; Sladek, K.; Fitzgerald, G.A. Increased excretion of leukotriene E4 during aspirin-induced asthma. J. Lab. Clin. Med., 1992, 119, 48-51.
128. Liu, J.Y.; Yang, J.; Inceoglu, B.; Qiu, H.; Ulu, A.; Hwang, S.H.; Chiamvimonvat, N.; Hammock, B.D. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem. pharmacol., 2010, 79, 880-887.
129. Wecksler, A.T.; Kenyon, V.; Deschamps, J.D.; Holman, T.R. Substrate specificity changes for human reticulocyte and epithelial 15-lipoxygenases reveal allosteric product regulation. Bio chemistry, 2008, 47, 7364-7375.
130. Wecksler, A.T.; Kenyon, V.; Garcia, N.K.; Deschamps, J.D.; van der Donk, W.A.; Holman, T.R. Kinetic and structural investigations of the allosteric site in human epithelial 15-lipoxygenase-2. Biochemistry, 2009, 48, 8721-8730.
131. Kozak, W.; Aronoff, D.M.; Boutaud, O.; Kozak, A. 11,12- epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Exp. Biol. Med. 2003, 228, 786-794.
132. Schmelzer, K.R.; Inceoglu, B.; Kubala, L.; Kim, I.H.; Jinks, S.L.; Eiserich, J.P.; Hammock, B.D., Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA, 2006, 103, 13646-13651.
133. Roumie, C.L.; Arbogast, P.G.; Mitchel, E.F., Jr.; Griffin, M.R. Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. J. Gen. Intern. Med., 2005, 20, 879-883.
134. Jung, O.; Jansen, F.; Mieth, A.; Barbosa-Sicard, E.; Pliquett, R.U.; Babelova, A.; Morisseau, C.; Hwang, S.H.; Tsai, C.; Hammock, B.D.; Schaefer, L.; Geisslinger, G.; Amann, K.; Brandes, R.P. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One, 2010, 5, e11979.
135. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
136. Millan, M.J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Therapeut., 2006, 110, 135-370.
137. Keith, C.T.; Borisy, A.A.; Stockwell, B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov., 2005, 4, 71-78.
138. Sreedhar, D., Subramanian, G., Udupa, N. Combination drugs: Are they rational? Curr. Sci.India, 2006, 91, 406.
139. Frantz, S. The trouble with making combination drugs. Nat. Rev. Drug Discov., 2006, 5, 881-882.
140. Bergmann, J.F., Review: Fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid. Based Med., 2008, 13, 18.
141. Morphy, R.; Rankovic, Z., Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15, 587-600.
142. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
143. Leval, X.; Julemont, F.; Delarge, J.; Pirotte, B.; Dogne, J.M. New trends in dual 5-LOX/COX inhibition. Curr. Med. Chem., 2002, 9, 941-962.
144. Brahams, D. Late benoxaprofen claims. Lancet, 1991, 337, 483-484.
145. Flynn, D.L.; Rafferty, M.F.; Boctor, A.M. Inhibition of 5-hydroxyeicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: Inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leukot. Med., 1986, 22, 357-360.
146. Flynn, D.L.; Belliotti, T.R.; Boctor, A.M.; Connor, D.T.; Kostlan, C.R.; Nies, D.E.; Ortwine, D.F.; Schrier, D.J.; Sircar, J.C. Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors. J. Med. Chem., 1991, 34, 518-525.
147. Janusz, J.M.; Young, P.A.; Ridgeway, J.M.; Scherz, M.W.; Enzweiler, K.; Wu, L.I.; Gan, L.; Darolia, R.; Matthews, R.S.; Hennes, D.; Kellstein, D.E.; Green, S.A.; Tulich, J.L.; Rosario-Jansen, T.; Magrisso, I.J.; Wehmeyer, K.R.; Kuhlenbeck, D.L.; Eichhold, T.H.; Dobson, R.L.; Sirko, S.P.; Farmer, R.W. New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3- dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Discovery and variation of the 5-keto substituent. J. Med. Chem., 1998, 41, 1112-1123.
148. Unangst, P.C.; Connor, D.T.; Cetenko, W.A.; Sorenson, R.J.; Kostlan, C.R.; Sircar, J.C.; Wright, C.D.; Schrier, D.J.; Dyer, R.D. Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl] methylene]oxazoles,-thiazoles, and-imidazoles: Novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J. Med. Chem., 1994, 37, 322-328.
149. Inagaki, M.; Tsuri, T.; Jyoyama, H.; Ono, T.; Yamada, K.; Kobayashi, M.; Hori, Y.; Arimura, A.; Yasui, K.; Ohno, K.; Kakudo, S.; Koizumi, K.; Suzuki, R.; Kawai, S.; Kato, M.; Matsumoto, S. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: Cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. J. Med. Chem., 2000, 43, 2040-2048.
150. Weisman, S.M.; Doyle, M.J.; Wehmeyer, K.R.; Hynd, B.A.; Eichhold, T.H.; Clear, R.M.; Coggeshall, C.W.; Kuhlenbeck, D.L. Effects of tebufelone (NE-11740), a new anti-inflammatory drug, on arachidonic acid metabolism. Agents Actions, 1994, 41, 156-163.
151. Unangst, P.C.; Shrum, G.P.; Connor, D.T.; Dyer, R.D.; Schrier, D.J. Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors. J. Med. Chem., 1992, 35, 3691-3698.
152. Janusz, J.M.; Young, P.A.; Ridgeway, J.M.; Scherz, M.W.; Enzweiler, K.; Wu, L.I.; Gan, L.; Chen, J.; Kellstein, D.E.; Green, S.A.; Tulich, J.L.; Rosario-Jansen, T.; Magrisso, I.J.; Wehmeyer, K.R.; Kuhlenbeck, D.L.; Eichhold, T.H.; Dobson, R.L. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations at the 5 position. J. Med. Chem., 1998, 41, 3515-3529.
153. Janusz, J.M.; Young, P.A.; Scherz, M.W.; Enzweiler, K.; Wu, L.I.; Gan, L.; Pikul, S.; McDow-Dunham, K.L.; Johnson, C.R.; Senanayake, C.B.; Kellstein, D.E.; Green, S.A.; Tulich, J.L.; Rosario-Jansen, T.; Magrisso, I.J.; Wehmeyer, K.R.; Kuhlenbeck, D.L.; Eichhold, T.H.; Dobson, R.L. New cyclooxygenase-2/5- lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethyl benzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations of the dihydrobenzofuran ring. J. Med. Chem., 1998, 41, 1124-1137.
154. Stanton, B.J.; Coupar, I.M. The effect of BW 755C and nordihydroguaiaretic acid in the rat isolated perfused mesenteric vasculature. Prostaglandins Leukot. Med., 1986, 25, 199-207.
155. Radmark, O.; Malmsten, C.; Samuelsson, B. The inhibitory effects of BW 755C on arachidonic acid metabolism in human polymorphonuclear leukocytes. FEBS lett., 1980, 110, 213-215.
156. Gulbenkian, A.R.; Fernandez, X.; Kreutner, W.; Minnicozzi, M.; Watnick, A.S.; Kung, T.; Egan, R.W. Anaphylactic challenge causes eosinophil accumulation in bronchoalveolar lavage fluid of guinea pigs. Modulation by betamethasone, phenidone, indomethacin, WEB 2086, and a novel antiallergy agent, SCH 37224. Am. Rev. Respir. Dis, 1990, 142, 680-685.
157. Argentieri, D.C.; Ritchie, D.M.; Ferro, M.P.; Kirchner, T.; Wachter, M.P.; Anderson, D.W.; Rosenthale, M.E.; Capetola, R.J. Tepoxalin: A dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J. Pharmacol. Exp. Ther., 1994, 271, 1399-1408.
158. Waldman, S.A.; Vitow, C.; Osborne, B.; Gillen, L.; Argentieri, D.C.; Wong, F.A.; Smith, I.L.; Chow, A.T.; Misiti, J.; Bjornsson, T.D. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. J. Clin. Pharmacol., 1996, 36, 462-468.
159. Knight, E.V.; Kimball, J.P.; Keenan, C.M.; Smith, I.L.; Wong, F.A.; Barrett, D.S.; Dempster, A.M.; Lieuallen, W.G.; Panigrahi, D.; Powers, W.J.; Szot, R.J. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam. Appl. Toxicol., 1996, 33, 38-48.
160. Beers, S.A.; Malloy, E.A.; Wu, W.; Wachter, M.; Ansell, J.; Singer, M.; Steber, M.; Barbone, A.; Kirchner, T.; Ritchie, D.; Argentieri, D. N-(5-substituted) thiophene-2-alkylsulfonamides as potent inhibitors of 5-lipoxygenase. Bioorg. Med, Chem., 1997, 5, 779-786.
161. Kirchner, T.; Argentieri, D.C.; Barbone, A.G.; Singer, M.; Steber, M.; Ansell, J.; Beers, S.A.; Wachter, M.P.; Wu, W.; Malloy, E.; Stewart, A.; Ritchie, D.M. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J. Pharmacol. Exp. Ther., 1997, 282, 1094-1101.
162. Le Filliatre, G.; Sayah, S.; Latournerie, V.; Renaud, J.F.; Finet, M.; Hanf, R. Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimu lation of the rat saphenous nerve. Br. J. Pharmacol., 2001, 132, 1581-1589.
163. Bailey, P.J.; Dallob, A.L.; Allison, D.L.; Anderson, R.L.; Bach, T.; Durette, P.L.; Hand, K.M.; Hopple, S.L.; Luell, S.; Meurer, R.; et al., Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phe nyl-ethenyl)-benzo (b)thiophene-2-carboxamide. Arzneimittel forschung, 1988, 38, 372-378.
164. Tischler, A.; Bailey, P.; Dallob, A.; Witzel, B.; Durette, P.; Rupprecht, K.; Allison, D.; Dougherty, H.; Humes, J.; Ham, E.; et al., L-652,343: A novel dual 5-lipoxygenase/cyclooxygenase inhibitor. Adv. Prostaglandin Thromboxane Leukot. Res., 1986, 16, 63-66.
165. Barr, R.M.; Black, A.K.; Dowd, P.M.; Koro, O.; Mistry, K.; Isaacs, J.L.; Greaves, M.W., The in vitro 5-lipoxygenase and cyclooxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin. Br. J. Clin. Pharmacol., 1988, 25, 23-26.
166. Gresele, P.; Arnout, J.; Deckmyn, H.; Vermylen, J. L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB4-production by stimulated human polymorphonuclear cells but not by stimulated human whole blood. Biochem. Pharmacol., 1987, 36, 3529-3531.
167. Chowdhury, M.A.; Abdellatif, K.R.; Dong, Y.; Das, D.; Suresh, M.R.; Knaus, E.E. Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2- dihydropyrid-2-one 5-lipoxygenase pharma cophore: Biological evaluation as dual inhibitors of cyclooxy genases and 5-lipoxygenase with anti-inflammatory activity. J. Med. Chem., 2009, 52, 1525-1529.
168. Chowdhury, M.A.; Abdellatif, K.R.; Dong, Y.; Das, D.; Yu, G.; Velazquez, C.A.; Suresh, M.R.; Knaus, E.E. Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxy benzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: Dual inhibitors of cyclo oxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg. Med. Chem. Lett., 2009, 19, 6855-6861.
169. Yu, G.; Praveen Rao, P.N.; Chowdhury, M.A.; Abdellatif, K.R.; Dong, Y.; Das, D.; Velazquez, C.A.; Suresh, M.R.; Knaus, E.E. Synthesis and biological evaluation of N-difluoromethyl-1,2-dihydropyrid-2-one acetic acid regioisomers: Dual inhibitors of cyclooxygenases and 5-lipoxygenase. Bioorg. Med. Chem. Lett., 2010, 20, 2168-2173.
170. Wylie, G.; Appelboom, T.; Bolten, W.; Breedveld, F.C.; Feely, J.; Leeming, M.R.; Le Loet, X.; Manthorpe, R.; Marcolongo, R.; Smolen, J. A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: A 24-week analysis of a 1-year clinical trial. Br. J. Rheumatol., 1995, 34, 554-563.
171. Aleo, M.D.; Wang, T.; Giebisch, G.; Sanders, M.J.; Walsh, A.H.; Lopez-Anaya, A. Model development and analysis of tenidapinduced proteinuria in the rat. J. Pharmacol. Exp. Ther., 1996, 279, 1318-1326.
172. Nelson, S.D. Structure toxicity relationships-how useful are they in predicting toxicities of new drugs? Adv. Exp. Med. Biol., 2001, 500, 33-43.
173. Fouda, H.G.; Avery, M.J.; Dalvie, D.; Falkner, F.C.; Melvin, L.S.; Ronfeld, R.A. Disposition and metabolism of tenidap in the rat. Drug. Metab. Dispos., 1997, 25, 140-148.
174. Lai, Y.; Ma, L.; Huang, W.; Yu, X.; Zhang, Y.; Ji, H.; Tian, J. Synthesis and biological evaluation of 3-[4-(amino/methyl sulfonyl)phenyl]methylene- indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 7349-7353.
175. Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Henichart, J.P. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett., 2002, 12, 779-782.
176. Rao, P.N.; Chen, Q.H.; Knaus, E.E. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: Dual inhibitors of cyclooxygenases and lipoxygenases. J. Med. Chem., 2006, 49, 1668-1683.
177. Chen, Q.H.; Rao, P.N.; Knaus, E.E. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs). Bioorg. Med. Chem., 2006, 14, 7898-7909.
178. Laufer, S.A.; Augustin, J.; Dannhardt, G.; Kiefer, W. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J. Med. Chem., 1994, 37, 1894-1897.
179. Cossy, J.; Belotti, D. Synthesis of ML-3000, an Inhibitor of Cyclooxygenase and 5-Lipoxygenase. J. Org. Chem., 1997, 62, 7900-7901.
180. Rotondo, S.; Dell'Elba, G.; Krauze-Brzosko, K.; Manarini, S.; Martelli, N.; Pecce, R.; Evangelista, V.; Cerletti, C. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function. Eur. J. Pharmacol., 2002, 453, 131-139.
181. Kulkarni, S.K.; Singh, V.P. Licofelone-A novel analgesic and antiinflammatory agent. Curr. Top. Med. Chem., 2007, 7, 251-263.
182. Alvaro-Gracia, J.M. Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheu matology, 2004, 43 Suppl 1, i21-25.
183. Vidal, C.; Gomez-Hernandez, A.; Sanchez-Galan, E.; Gonzalez, A.; Ortega, L.; Gomez-Gerique, J.A.; Tunon, J.; Egido, J. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J. Pharmacol. Exp. Ther., 2007, 320, 108-116.
184. Koeberle, A.; Siemoneit, U.; Buhring, U.; Northoff, H.; Laufer, S.; Albrecht, W.; Werz, O., Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J. Pharmacol. Exp. Ther., 2008, 326, 975-982.
185. Samuelsson, B.; Morgenstern, R.; Jakobsson, P.J., Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol. Rev., 2007, 59, 207-224.
186. Hwang, S.H.; Wagner, K.M.; Morisseau, C.; Liu, J.Y.; Dong, H.; Wecksler, A.T.; Hammock, B.D. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J. Med. Chem., 2011, 54, 3037-3050.
187. Moser, D.; Wisniewska, J.M.; Hahn, S.; Achenbach, J.; Buscato, E.; Klingler, F.M.; Hofmann, B.; Steinhilber, D.; Proschak, E. Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering. ACS Med. Chem. Lett., 2012, 3, 155-158.
188. Cheng, Y.; Wang, M.; Yu, Y.; Lawson, J.; Funk, C.D.; Fitzgerald, G.A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest., 2006, 116, 1391-1399.
189. Liedtke, A.J.; Keck, P.R.; Lehmann, F.; Koeberle, A.; Werz, O.; Laufer, S.A. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J. Med. Chem., 2009, 52, 4968-4972.
190. Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Med. Chem., 2008, 51, 8068-8076.
191. Greiner, C.; Zettl, H.; Koeberle, A.; Pergola, C.; Northoff, H.; Schubert-Zsilavecz, M.; Werz, O. Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1. Bioorg. Med. Chem., 2011, 19, 3394-3401.
192. Koeberle, A.; Rossi, A.; Zettl, H.; Pergola, C.; Dehm, F.; Bauer, J.; Greiner, C.; Reckel, S.; Hoernig, C.; Northoff, H.; Bernhard, F.; Dotsch, V.; Sautebin, L.; Schubert-Zsilavecz, M.; Werz, O. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio) octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Pharmacol. Exp. Ther., 2010, 332, 840-848.
193. Wu, Y.; He, C.; Gao, Y.; He, S.; Liu, Y.; Lai, L. Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors. J. Med. Chem., 2012, 55, 2597-2605.
194. McGee, J.E.; Fitzpatrick, F.A. Erythrocyte-neutrophil interactions: Formation of leukotriene B4 by transcellular biosynthesis. Proc. Natl. Acad. Sci. USA, 1986, 83, 1349-1353.
195. Chen, Z.; Wu, Y.; Liu, Y.; Yang, S.; Chen, Y.; Lai, L. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase. J. Med. Chem., 2011, 54, 3650-3660.
196. Hibi, S.; Okamoto, Y.; Tagami, K.; Numata, H.; Kobayashi, N.; Shinoda, M.; Kawahara, T.; Murakami, M.; Oketani, K.; Inoue, T.; et al. Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: Synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole deriva tives. J. Med. Chem., 1994, 37, 3062-3070.
197. Hibi, S.; Okamoto, Y.; Tagami, K.; Numata, H.; Kobayashi, N.; Shinoda, M.; Kawahara, T.; Harada, K.; Miyamoto, K.; Yamatsu, I. Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J. Med. Chem., 1996, 39, 3148-3157.
198. Draper, N.; Stewart, P.M. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J. Endocrinol., 2005, 186, 251-271.
199. Marino, J.P.B., C.A.; Eidam, P.; Mcatee, J.J. sEH AND 11-HSD1 DUAL INHIBITORS. WO 2010/011917 A1, July 25 2008, 2008.
200. Liu, J.Y.; Park, S.H.; Morisseau, C.; Hwang, S.H.; Hammock, B.D.; Weiss, R.H. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol. Cancer Ther., 2009, 8, 2193-2203.
201. Warner, T.D.; Mitchell, J.A. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal antiinflammatory drugs. Lancet, 2008, 371, 270-273.
202. Marnett, L.J. The COXIB experience: A look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 265-290.
203. Gilbert, N.C.; Bartlett, S.G.; Waight, M.T.; Neau, D.B.; Boeglin, W.E.; Brash, A.R.; Newcomer, M.E. The structure of human 5-lipoxygenase. Science, 2011, 331, 217-219.